Biomarkers /
CDH11
Overview
Cadherin 11, type 2, OB-cadherin (osteoblast) (CDH11) is a gene that encodes a protein that mediates calcium-dependent cell-cell adhesion. Missense mutations, silent mutations, fusions, nonsense mutations, and frameshift deletions are observed in cancers such as colon cancer, stomach cancer, and skin cancer.
CDH11 is altered in 0.35% of all cancers with high grade ovarian serous adenocarcinoma, endometrial endometrioid adenocarcinoma, breast invasive ductal carcinoma, colon adenocarcinoma, and bladder urothelial carcinoma having the greatest prevalence of alterations [3].
The most common alterations in CDH11 are CDH11 K293E (1.06%), CDH11 V147D (1.08%), CDH11 E140G (0.94%), CDH11 R137Q (0.94%), and CDH11 V149D (0.94%) [3].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.